Cite
HARVARD Citation
Dimopoulos, M. et al. (n.d.). Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet oncology. 18 (2), pp. 241-250. [Online].